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Abstract
Background: Resistance of Leishmania donovani to pentavalent antimonials, the first-line treatment of visceral leishmaniasis
(VL), has become a critical issue worldwide. Second-line and new drugs are also not devoid of limitations. Suitable drug-
delivery systems can improve the mode of administration and action of the existing antimonials, thus increasing their
clinical life.
Methodology/Principal Findings: We investigated the efficacy of sodium stibogluconate (SSG) in phosphatidylcholine (PC)–
stearylamine-bearing liposomes (PC-SA-SSG), PC-cholesterol liposomes (PC-Chol-SSG) and free amphotericin B (AmB)
against SSG-resistant L. donovani strains in 8-wk infected BALB/c mice. Animals were sacrificed and parasites in liver, spleen
and bone marrow were estimated 4-wk post-treatment by microscopic examination of stamp smears and limiting dilution
assay. A set of PC-SA-SSG and AmB treated mice were further studied for protection against reinfection. Serum antibodies
and cytokine profiles of ex-vivo cultured splenocytes were determined by ELISA. Uptake of free and liposomal SSG in
intracellular amastigotes was determined by atomic absorption spectroscopy. Rhodamine 123 and 5-carboxyfluorescein,
known substrates of Pgp and MRP transporter proteins, respectively, were used in free and liposomal forms for efflux
studies to estimate intracellular drug retention. Unlike free and PC-Chol-SSG, PC-SA-SSG was effective in curing mice
infected with two differentially originated SSG-unresponsive parasite strains at significantly higher levels than AmB.
Successful therapy correlated with complete suppression of disease-promoting IL-10 and TGF-b, upregulation of Th1
cytokines and expression of macrophage microbicidal NO. Cure due to elevated accumulation of SSG in intracellular
parasites, irrespective of SSG-resistance, occurs as a result of increased drug retention and improved therapy when
administered as PC-SA-SSG versus free SSG.
Conclusions/Significance: The design of this single-dose combination therapy with PC-SA-SSG for VL, having reduced
toxicity and long-term efficacy, irrespective of SSG-sensitivity may prove promising, not only to overcome SSG-resistance in
Leishmania, but also for drugs with similar resistance-related problems in other diseases.
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Introduction
Leishmaniasis is a disease caused by different species of
protozoa of the genus Leishmania that are transmitted by
Phlebotomine sandflies. It has traditionally been classified in three
different clinical forms, visceral (VL), cutaneous (CL) and
mucocutaneous leishmaniasis (MCL), which have different
immunopathologies and degrees of morbidity and mortality. VL
is caused by Leishmania donovani in the Indian subcontinent, Asia,
and Africa, L. infantum in the Mediterranean basin, and L. chagasi in
South America and is usually fatal if left untreated [1,2]. In the
absence of vaccines, pentavalent antimonials like sodium stiboglu-
conate (SSG) and meglumine antimoniate remain the first line
therapy for CL and VL for over half a century, and are still in use
in many parts of the world. The prolonged treatment requiring
parenteral administration, toxicity, and the emergence of signif-
icant resistance are all factors limiting the drugs’ usefulness [3].
Although few other options are available such as amphotericin B
(AmB), miltefosine, paromomycin, and lipid-conjugated formula-
tions of AmB, they also suffer from one or more limitations [4–7].
Approaches to overcome antimonial resistance include use of
alternative drugs which as mentioned earlier, are not devoid of
limitations, or combination therapy having synergistic effects to
check the further development of resistance [8–12]. Additionally,
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effective therapies against SSG-resistant parasites include reversing
their resistant nature with verapamil or buthionine sulfoximine in
combination with SSG [13,14]. Reports of resistance development
towards newer drugs [15], considerable variation in resistance
mechanisms in field isolates [16], and lack of progress in drug
discovery add to the severity of the problem. A lot of research has
focused on understanding the probable mechaninsms of drug
resistance in Leishmania with main focus on SSG resistance. The
reason for the emergence of resistance seems complex and
multifactorial. As reviewed by Croft et al. [8], reduction of drug
concentration within the parasite, either by decreasing drug
uptake or by increasing efflux/sequestration of the drug,
constitutes the primary mechanism of antimonial resistance; other
potential resistance mechanisms include inhibition of drug
activation, inactivation of active drug, and gene amplification. In
the light of the above complications, improvement in the mode of
administration and action of the existing and proven antileishma-
nials can become an important strategy in the management of VL
[17].
Liposomes are artificially prepared vesicles made of lipid
bilayer. They can act as targeted drug delivery agents to
macrophages in parasitic infections [18]. Liposomal SSG formu-
lations against SSG-responsive parasites have been shown to
enhance the antileishmanial activity of free SSG [19–25]. Carter et
al. reported a differential organ dependent activity of non-ionic
vesicular formulation of SSG in some clinical isolates of Leishmania
which did not respond to free SSG [26], but information on the
development of long lasting protective cure against SSG-resistant
parasite infection with liposomal SSG therapy is lacking. Earlier,
we reported that cationic liposomes with egg phosphatidylcholine
(PC) and stearylamine (SA) had leishmanicidal activity [27,28] and
entrapment of SSG (PC-SA-SSG) enhanced their potentiality
against chronic VL in in vivo murine model [29]. PC-SA
liposomes kill Leishmania by specific interaction with surface
phosphatidylserine (PS) of promastigotes and amastigotes [30].
We had earlier reported on the successful immunomodulation of
the host with a liposomal AmB formulation as a curative strategy
in treating SSG-responsive VL infection [31]. Moreover, lipo-
somes with their slow release property are known to circumvent
the membrane efflux pathways thus increasing the intracellular
retention of drug [32].
In the present study we compared the potential of single dose
PC-SA-SSG therapy with PC-cholesterol formulation (PC-Chol-
SSG) and AmB against SSG-resistant L. donovani GE1F8R and
CK1R infection in BALB/c mice. These data add a new
dimension to the therapy of SSG-unresponsive L. donovani
infection. The insight into the probable mechanisms by which
PC-SA associated drug works gives a broader perspective to this
study in aiming other infections with similar immunological
profiles and drug resistant phenotypes.
Materials and Methods
Animals and parasites
BALB/c mice and Golden Syrian hamsters, bred in the animal
facility of Indian Institute of Chemical Biology, Kolkata, India,
were used for the studies. The studies were approved by the
Institute’s Animal Ethical Committee (147/1999/CPCSEA) and
animals were handled according to their guidelines. L. donovani
SSG-sensitive AG83 (MHOM/IN/1983/AG83) and resistant,
GE1F8R (cloned from MHOM/IN/1989/GE1) and CK1R
(isolated as MHOM/IN/1995/CK from a SSG-unresponsive
patient) strains were maintained in vivo by intracardiac injection
into hamsters [33]. Transformation of amastigotes from infected
hamster spleen to promastigotes was carried out at 22uC in
medium-199 (Sigma-Aldrich, St. Louis, MO) supplemented with
penicillin G sodium (l00 U/ml), streptomycin sulfate (100 mg/ml)
and 10% heat inactivated fetal bovine serum (FBS) (Sigma-
Aldrich) and subcultured in the same medium [31].
Entrapment of SSG, rhodamine 123, and 5-
carboxyfluorescein in liposomes
Liposomes were prepared with PC form egg yolk and
Cholesterol (Sigma-Aldrich) or SA (Fluka, Buchs, Switzerland) at
7:2 molar ratios, respectively. For encapsulation of SSG
(Gluconate Health Limited, Kolkata, India) the lipid film
containing 20 mg of PC was mixed with either 2 mg of SA or
3 mg of Chol and dispersed in 0.02 M phosphate buffered saline
(PBS) pH 7.4 containing 1 mg/ml of SSG and sonicated in an
ultrasound probe sonicator (Misonix, Farmingdale, NY) for 2 min
with intervals on ice. Unentrapped SSG was removed by
centrifuging thrice at 60,0006g, for 30 min each [29]. The
amount of SSG entrapped in PC-SA and PC-Chol liposomes as
determined colorimetrically [29], ranged from 15 to 20 mg/mg of
PC and the efficiency of entrapment was approximately 30 to
40%. To entrap rhodamine 123 (Rh 123) (Calbiochem, San
Diego, CA) in PC-SA (PC-SA-Rh 123), freshly prepared Rh 123
solution in chloroform was added to the lipids [34] and liposome
was prepared as described above. For entrapment of 5-carboxy-
fluorescein (CF) (Sigma), lipid film was dispersed in PBS
containing 50 mM CF [35] and liposomes were prepared as
above. The entrapment efficiency estimated from a standard curve
of the respective dyes after disrupting the liposomes with 1%
TritonX-100 (Sigma) and measuring the fluorescence intensity
with Fluorescence spectrophotometer (F-7000 FL spectrophotom-
eter, Hitachi High Technologies, Japan) (505 nm/535 nm for Rh
123 and 492 nm/517 nm for CF) was found to be nearly 90% for
Rh 123 containing liposome and 75% for CF containing liposome.
In vitro antileishmanial assay and quantification of
intracellular SSG of amastigotes
Peritoneal macrophages isolated from BALB/c mice were
pooled and cultured at 37uC in 5% CO2 in RPMI-1640 (Sigma-
Aldrich) supplemented with FBS and antibiotics as described
above. SSG-sensitive AG83 and resistant GE1F8R promastigotes
were allowed to infect peritoneal macrophages (10:1) for 3 h.
Infected cells were thereby treated with various doses of liposomal
or free SSG, for 72 h at 37uC. The cells were then fixed and
stained with Giemsa for microscopic determination of intracellular
parasite numbers per 200 host cells [29]. In parallel sets of
experiments, cells were scraped and amastigotes were freed from
their host cells, as described [36]. Dried amastigotes were digested
with nitric acid overnight and diluted with deionised water for
antimony analysis by atomic absorption spectroscopy (AAS)
(Perkin-Elmer 4100 ZL, CA, USA) [37].
Dye uptake and retention assay
Rh 123 uptake and retention studies were performed according
to Kang et al. with slight modifications [34]. L. donovani AG83 and
GE1F8R promastigotes were washed and resuspended (26105
parasites/ml) in serum free M-199, and incubated along with
different concentrations of free Rh 123 for indicated periods of
time at 22uC. For retention studies, parasites were incubated with
250 ng/ml of free or entrapped Rh 123 for 4 h, washed and
further incubated in media free of Rh 123. In case of CF, cells
were preincubated with 2 mM of the dye [38]. At indicated time
points, parasites were washed thrice in PBS and finally lysed in
Cure against SSG-Resistant Leishmania Infection
PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e17376
0.1% Triton X-100. The intracellular dye concentrations were
determined by measuring fluorescence intensity of the cell lysates
and comparing them with the standard curves as above. The
percent retention of free vs liposomal dyes were calculated with
respect to controls.
Infection of mice and treatment regimen
For experimental infections, BALB/c mice (4–6 weeks) were
injected via the tail vein with 2.56107 hamster spleen-derived L.
donovani amastigotes (in 200 ml 0.02 M PBS/mouse), and for
reinfection, the same number of amastigotes were injected 12-wk
after the primary infection. Eight weeks postinfection, groups of
animals were treated intravenously with either 300 mg/kg of free
SSG, or 12 mg/kg of SSG entrapped in PC-SA or PC-Chol
liposomes. Amphotericin B deoxycholate (AmB) (kind gift from R.
P. Goswami and B. Saha of School of Tropical Medicine, Kolkata,
India) was administered intravenously at a single dose of 2 mg/kg/
mice. Mice were sacrificed 4-wk post-treatment, and spleen and
liver parasitic loads were determined from Giemsa-stained
impression smears and reported as Leishman Donovan Units
(LDU), calculated as the number of parasites per 1000 nucleated
cells x organ weight (in mg) [31,39]. In selected groups, a weighed
piece of spleen or liver from experimental mice was first
homogenized in Schneider’s Drosophila medium (Invitrogen
Corporation, Carlsbad, CA) supplemented with 10% FBS, and
then diluted in the same medium to a final concentration of 1 mg/
ml. Five-fold serial dilutions of the homogenized tissue suspensions
were plated in 96-well plates and incubated at 22uC for 21days,
with periodic checking at 7-day intervals for viable and motile
promastigotes. The reciprocal of the highest dilution that was
positive for parasites was considered to be the parasite concentra-
tion per milligram of tissue. The total organ parasite burden was
calculated using the weight of the respective organs [31]. Infection
in bone marrow was calculated as parasites/1000 host cell nuclei
[31]. Mice reinfected at 4-wk post-treatment were sacrificed at 20-
wk of initial infection and organ parasite burden was determined
as above.
Detection of IgG isotype levels in the serum
Mice were bled 4 wk after treatment, and sera were stored at -
20uC until use. Antigen-specific serum immunoglobulin (Ig)-G
isotype antibody response was measured by conventional ELISA
as described [31]. Briefly, 96-well ELISA plates (Maxisorp, Nunc,
Roskilde, Denmark) incubated overnight at 4uC with 2.5 mg/well
Leishmania membrane antigen (LAg) [31], were blocked and further
incubated with mice sera (1:1000 dilutions) for 1 h, washed
thoroughly, followed by 1 h incubation at 37uC with peroxidase-
conjugated goat anti-mouse IgG1 or IgG2a antibodies (BD
Pharmingen, San Diego, CA). The plates were then developed
for color reaction with substrate solution (o-phenylenediamine
dihydrochloride, 0.8 mg/ml in phosphate-citrate buffer (pH 5.0),
containing 0.04% H2O2) for 30 min, and absorbance was
measured on ELISA plate reader (Thermo Electron Corporation,
Waltham, MA) at 450 nm.
Splenocyte-proliferation and analysis of cytokines
Splenocyte-proliferation assay was performed for different
experimental groups. Cell suspension was prepared by mechan-
ical disruption of spleen, followed by red blood corpuscles (RBC)
lysis with 0.14 M Tris buffered NH4Cl. After several washings in
RPMI 1640 medium, cells were resuspended in complete
medium (RPMI 1640 supplemented with 10% FBS, l00 U/ml
penicillin G sodium, 100 mg/ml streptomycin sulfate and
50 mM b-mercaptoethanol [Sigma-Aldrich]). Viable mononu-
clear cell number was determined by counting Trypan blue
unstained cells in a hemocytometer. Cells were plated in
triplicate at 26106 cells/ml concentrations in 96-well plates
(Nunc, Roskilde, Denmark) and allowed to proliferate for 72 h
at 37uC in 5% CO2 incubator in presence of 12.5 mg/ml LAg
[40]. Cells were pulsed further for 18 h with 0.5 mCi of [3H]
thymidine/well (Amersham Biosciences, Buckingham-shire, UK),
harvested on glass fiber paper, and radioactivity was measured
in a liquid scintillation counter (Beckman Instruments, Fullerton,
CA). In parallel experiments, cytokine production by splenocytes
was determined by ELISA kit (BD Biosciences, San Diego, CA),
as per manufacturer’s instruction. For in vitro depletion, total
splenocytes were incubated with 1 mg/106 cells of anti-CD4+ or
anti-CD8+ mAbs (BD Biosciences) for 1 h at 4uC. Cells were
washed and cultured in LAg as above. The efficacy of depletion
was documented on each experiment by flow cytometry.
Splenocytes from normal mice were cultured similarly in
complete medium with different doses of free SSG or entrapped
in PC-SA and PC-Chol liposomes for 48 h with or without LPS
(2.5 mg/ml) [31] and cytokine production was determined as
above.
Quantification of Nitric Oxide
Nitric oxide (NO) content in the culture supernatants from LAg-
pulsed splenocytes cultured for 72 h was analyzed by Griess assay
method according to Ding et. al., using NaNO2 diluted in culture
medium as standard [41]. Briefly, the mixture of Greiss reagent
(1% sulfanilamide and 0.1% N-(1-naphthyl) ethylenediamine
dihydrochloride in 2.5% H3PO4) and culture supernatant at 1:1
ratio was incubated for 15 min at room temperature, and the OD
was determined at 550 nm by ELISA reader (Thermo Electron
Corporation, Waltham, MA).
Statistical analysis
Statistical analyses were done using GraphPad Prism (Graph-
Pad Software,v.5.0, San Diego, CA) software. A two-tailed
Student’s t-test was used to compare the significance between
two groups. A one-way ANOVA (non-parametric) was used to
compare more than two groups, followed by Tukey’s multiple
comparison test. Differences were considered statistically signifi-
cant at p,0.05.
Results
Cure and protection against reinfection conferred by PC-
SA-associated SSG against drug-resistant L. donovani
infection in mice
Earlier we reported a profound synergistic activity of SSG
entrapped in PC-SA liposome in both in vitro and in vivo
models of SSG-non-resistant VL [29]. Here, therapeutic
potency of PC-SA-SSG was compared with other formulations
in susceptible BALB/c mice infected with virulent strains of
SSG-resistant L. donovani, GE1F8R and CK1R, to validate the
strain-independent efficacy of PC-SA-SSG. Progressively infect-
ed mice on treatment with free SSG and PC-Chol-SSG failed to
suppress parasite load in GE1F8R, although they showed partial
activity against CK1R strain (Figure 1). Interestingly, PC-SA-
SSG suppressed liver parasitic load by 93% and 97%,
respectively in GE1F8R and CK1R infected mice, which were
comparable to AmB therapy (Figure 1A, D). In contrast to free
SSG and PC-Chol-SSG, significant suppression with PC-SA-
SSG was also achieved in spleen (98% and 96%) (Figure 1B, E)
and bone marrow (84% and 86%) (Fig. 1C, F) of GE1F8R
and CK1R infected mice respectively (p,0.05). Strikingly, the
Cure against SSG-Resistant Leishmania Infection
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more sensitive limiting dilution assay demonstrated superiority
of PC-SA-SSG over AmB in suppressing liver and splenic
parasite burden (Figure 1G) in both GE1F8R and CK1R
infected mice (p,0.05). To further strengthen our findings,
8-wk-infected BALB/c mice treated with PC-SA-SSG and AmB
were re-infected with GE1F8R intravenously 4-wk after therapy.
Age-matched normal mice were also infected simultaneously
and were considered as age-matched controls. In comparison
to AmB, mice treated with PC-SA-SSG were more resistant to
re-infection with GE1F8R (p,0.05) (Figure 2A, B). We
observed only a slight increase in liver and spleen parasite
burden in the PC-SA-SSG-treated group till 20-wk of initial
infection.
In vitro antileishmanial activity and differential
accumulation of SSG induced by PC-SA and PC-Chol
liposomes
In accordance to our in vivo findings, PC-SA-SSG could induce
significantly higher suppression towards parasite infection
(p,0.05) compared to PC-Chol-SSG treatment in both SSG-
sensitive AG83 and SSG-resistant GE1F8R infected macrophages
(Figure 3A). SSG resistance in Leishmania involves reduction in
Figure 1. Parasite burden in treated BALB/c mice after L. donovani challenge infection. Parasite loads of liver, spleen, and bone marrow in
murine model of established visceral leishmaniasis after treatment with 300 mg/kg of free sodium stibogluconate (SSG), 12 mg/kg of SSG entrapped
in phosphatidylcholine-stearylamine (PC-SA) or phosphatidylcholine-cholesterol (PC-Chol) liposomes and 2 mg/kg amphotericin B (AmB). Mice were
infected with L. donovani amastigotes of either GE1F8R or CK1R strains. At 8 week postinfection (p.i.) mice were treated with a single dose of various
drugs by intravenous injection. Mice were sacrificed after 4 weeks of treatment for determination of (A, D) liver, (B, E) spleen, and (C, F) bone marrow
parasite loads. Untreated, infected mice were used as controls. Liver and spleen parasite burden were determined by stamp-smear method and
expressed as Leishman Donovan Units (LDU), and bone marrow parasite load in cell smear prepared from femur bone marrow and expressed as
amastigotes/1000 bone marrow nuclei. Data represent mean 6 SEM (n = 5 mice per group), representative of two similar experiments. * p,0.05;
** p,0.01; *** p,0.001. (G) Eight week infected mice received optimal SSG, PC-SA-SSG and AmB. Parasite burden determined 12 weeks following
infection reflects the mean log10 parasite burden 6 SEM determined by the limiting dilution assay (LDA) (n = 5 mice per group) with PBS treated
group as control. Data are representative of two similar experiments. * p,0.05 compared to AmB therapy.
doi:10.1371/journal.pone.0017376.g001
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intracellular SSG accumulation, either as a result of its reduced
influx or increased efflux from the parasite and/or macrophages
[4]. The suppression in parasite infection as observed in our
experiments was associated with an elevated accumulation of SSG
in the intracellular amastigotes of both AG83 and GE1F8R
(p,0.05) parasites compared to PC-Chol-SSG as measured by
AAS (Figure 3B). Free SSG on the other hand showed negligible
antileishmanial activity, accompanying poor drug accumulation
within resistant GE1F8R, compared to sensitive AG83 (Figure 3C,
D) (p,0.05).
PC-SA incorporation increases retention of rhodamine
123 and 5-carboxyfluorescein in Leishmania
We and others have demonstrated the increased efficacy of
vesicular SSG in the treatment of VL [19-25,26]. The exact
mechanism by which this strategy works however remains to be
studied. One of the mechanisms is the entrapment of drugs in
liposomes, which results in circumvention of Pgp mediated drug
efflux, and is well demonstrated in cancer therapy [34]. Drug
resistance in Leishmania has been variously described and involves
active efflux systems working in the parasite and/or macrophages
[4]. Thus we speculated that entrapment of SSG in PC-SA can
prevent its exposure to the active pumps in turn increasing its
intracellular concentration. To investigate if PC-SA can circum-
vent the resistance mechanism active in the parasite, we used Rh
123 and CF, substrates for Pgp and MRP family respectively. Rh
123 concentrations of 250 ng/ml and uptake time of 4 h were
chosen from the dose and time kinetic studies using free Rh 123
(Figure 4A, B). When AG83 and GE1F8R parasites, preincubat-
ed with either free Rh 123 or PC-SA-Rh 123, were again
incubated in dye-free medium, the intracellular Rh 123
concentration decreased with time regardless of the parasite
strain (Figure 4C). However, the fall was faster and greater in
GE1F8R compared to AG83 for free Rh 123. Interestingly,
loading Rh 123 into PC-SA liposome although showed no
difference compared to free dye in AG83, it significantly
increased the retention capacity of GE1F8R (1.6 to1.8 folds
between 0.5 to 1.5 h) (p,0.05 to 0.001). Loading the liposomes
with CF produced a similar profile in SSG-unresponsive
parasites. When GE1F8R promastigotes preincubated with the
free dye were further incubated in dye free medium,
65.561.55%, 57.2761.714%, and 37.5761.068% dye were
retained after 0.5 h, 1 h and 1.5 h respectively. When liposomal
CF was used the retention increased to 83.2161.76%,
74.2862.73%, and 67.2361.28%, with a significant rise of 0.8
to 0.6 folds between 0.5 h and 1.5 h (p,0.01 to 0.001). Free Rh
123 was effluxed out more vigorously then free CF till 1 h of
incubation after which CF levels dropped to 37%.
Immunomodulatory effects of PC-SA-SSG on normal
mice splenocytes
The protective chemotherapeutic response demonstrated by
PC-SA-SSG prompted us to investigate its possible immunomod-
ulatory role in vitro. As reported earlier [42], SSG could suppress
the disease promoting IL-10 production in normal LPS-pulsed
splenocytes (Figure 5A). SSG (0.36 mg/ml) entrapped in PC-SA
(20 mg/ml) further brought about a 1.7-fold higher reduction in
IL-10 compared to equivalent amount of free SSG (Figure 5B).
PC-Chol on the other hand, masked the ability of entrapped SSG
to bring down IL-10 (Figure 5C).
Humoral response in PC-SA-SSG treated mice
IgG2a levels are dependent on IFN-c, whereas IgG1 levels
correlate with IL-4. IgG2a and IgG1 are therefore used as
surrogate markers for Th1 and Th2 responses [43]. PC-SA-SSG
treatment mounted 2 and 1.3-fold (p,0.05) higher Leishmania
membrane antigen (LAg)-specific IgG2a compared to respective
GE1F8R, and CK1R-infected controls, and almost steady IgG1
levels concomitant with a steady secretion of IL-4. Similar results
were also observed in mice treated with AmB, but not with PC-
Chol-SSG treatment (Figure 6A, B).
Figure 2. Parasite burden in cured BALB/c mice after reinfec-
tion with L. donovani. Cured mice (PC-SA-SSG and AmB treated) after
4 weeks of treatment along with naı¨ve age-matched controls were
reinfected with similar dose of virulent amastigotes and at 20 weeks of
primary infection, were sacrificed and liver (A) and spleen (B) parasitic
loads were determined by stamp-smear method and expressed as
Leishman Donovan Units (LDU). Data represent mean 6 SEM (n = 3-5
mice per group), representative of two similar experiments. * p,0.05;
** p,0.01; *** p,0.001.
doi:10.1371/journal.pone.0017376.g002
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PC-SA-SSG-driven antigen-specific proliferative response
Impairment of cell-mediated immune response in active VL
patients is reflected by marked T cell anergy specific to Leishmania
antigens [31,44] which is reversed by successful therapy. To
investigate whether PC-SA-SSG can do so, we performed LAg-
specific T cell proliferation assay. In contrast to PC-Chol-SSG
therapy, PC-SA-SSG triggered 11 and 12-fold higher LAg-specific
proliferation compared to respective GE1F8R and CK1R infected
mice (Figure 6C, D), which were even higher than AmB treatment
(p,0.05). The proliferative response was significantly blocked
individually by both anti-CD4+ and anti-CD8+ antibodies inferring
that marked proliferation was contributed by both subsets of T cells.
Cyokine response and NO production
To compare the type of immunological response in L. donovani-
infected mice with PC-SA-SSG liposome treated mice, detailed
analysis of cytokine production was conducted in splenocytes of
differently treated infected animals by ELISA at 12-wk post-
infection. A general Th1 dominance in PC-SA-SSG treated mice
was evident from 18 and 16-fold higher Interferon (IFN)-c
secretion from LAg-pulsed splenocytes, than respective GE1F8R
and CK1R-infected mice (Figure 7A, C) (p,0.05) which was
comparable with AmB therapy. In contrast, PC-Chol-SSG treated
mice expressed no enhancement of IFN-c. In vitro CD4+and
CD8+ T cell depletion demonstrated significant role of the
dichotomous T cell subsets in IFN-c expression (Figure 7E).
Elevated IFN-c in PC-SA-SSG and AmB treated mice corre-
sponded with a simultaneous upregulation of interleukin (IL)-12
and tumor necrosis factor (TNF)-a expression. IL-12 levels were
elevated by 3.5 and 4-fold (p,0.05) and TNF-a levels showed 1.5
and 1.8-fold increase in PC-SA-SSG treated mice, compared to
GE1F8R and CK1R-infected mice (Figure 7A, C).
Figure 3. Parasite suppression in L donovani-infected macrophages and SSG accumulation in intramacrophagic amastigotes. Both
AG83 and GE1F8R infected peritoneal macrophages were treated with (A, B) PC-SA-SSG, PC-Chol-SSG, and (C, D) free SSG for 72 h. (A, B) The
treatment-induced percentage suppression of parasites was calculated in comparison to respective untreated-control. (B, D) Total SSG uptake by
intramacrophagic amastigotes following various treatments was estimated by atomic absorption spectroscopy (AAS), and represented as nanogram
(ng)/106 cells. Data represent the mean 6 SEM of three independent experiments. * p,0.05 compared to AG83 and GE1F8R strains treated with PC-
Chol-SSG.
doi:10.1371/journal.pone.0017376.g003
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Figure 5. Immunomodulatory activity of free and vesicular SSG on splenocytes of normal BALB/c mice. Splenocytes of normal healthy
mice were incubated with various concentrations of (A) free SSG, (B) PC-SA-SSG, and (C) PC-Chol-SSG with or without LPS (2.5 mg/ml) for 48 h at 37uC
with 5% CO2. IL-10 was measured from culture supernatants by enzyme-linked immunosorbent assay (ELISA). Each symbol represents mean cytokine
level 6 SEM, representative of three independent experiments.
doi:10.1371/journal.pone.0017376.g005
Figure 4. Intracellular retention of free and liposomal rhodamine 123 in L.donovani promastigotes. Rhodamine 123 (Rh123) uptake and
retention study was performed in AG83 and GE1F8R strains with Rh123. Parasites were incubated with (A) different concentrations of free Rh123 for
4 h and (B) for different time periods. At indicated time points parasites were washed, lysed and fluorescence intensity of the cell lysates measured.
Data reperesent mean 6 SEM of two independent experiments performed in triplicates and expressed as ng of Rh123/105 cells. (C, D) In another set
of experiments, parasites incubated for 4 h with 250 ng/ml of either free or liposomal Rh123 were washed and reincubated in medium free of Rh 123
for different times followed by lysis. The percent retention of Rh123 was calculated for each group compared to respective controls. Data represent
mean 6 SEM of three independent experiments each performed in duplicate. * p,0.05; *** p,0.001.
doi:10.1371/journal.pone.0017376.g004
Cure against SSG-Resistant Leishmania Infection
PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e17376
We next investigated the altered expression of immunosuppres-
sive cytokines of treated mice. Despite sustained levels of IL-4, PC-
SA-SSG treated mice expressed negligible IL-10 (p,0.05) and
transforming growth factor (TGF)-b compared to GE1F8R and
CK1R-infected mice (Figure 7B, D). In vitro blocking demon-
strated CD4+ cells as the main source of IL-10 (Figure 7F). In
comparison AmB could only partially suppress the disease
promoting cytokines, IL-10 and TGF-b highlighting the better
curative response of PC-SA-SSG therapy. Failure to suppress IL-
10 and TGF-b accounted for poor outcome of the therapy with
PC-Chol-SSG (Figure 7B, D).
NO is the crucial killing effector molecule against leishmaniasis
produced by IFN-c-stimulated and NO synthase-induced classical
macrophages. Th1 dominance in PC-SA-SSG treated mice
correlated with 6-fold higher NO production than infected
control, which was significantly higher than AmB treated group
(Figure 7G) (p,0.05). The strong ability to suppress disease
promoting IL-10 and to effectively trigger macrophage microbi-
cidal molecule NO thus reversing the immunosuppressive
condition towards Th1 type immune response, accounts for the
radical cure elicited by PC-SA-SSG.
Discussion
In this study we evaluated a new therapeutic approach with
cationic liposomal SSG against SSG-resistant L. donovani parasites.
Therapy with a single dose of SSG in PC-SA liposomes led to the
successful cure of progressive SSG-resistant VL in BALB/c mice
that was even better than AmB therapy in providing effective
antileishmanial immunity and strong protection against reinfec-
tion. In contrast, equivalent amount of SSG in PC-Chol liposomes
failed to evoke significant cure. Investigation into the probable
mechanisms demonstrated that PC-SA-SSG could directly kill
parasites irrespective of SSG-sensitivity owing to the leishmanici-
dal effect of PC-SA combined with higher accumulation of SSG
within the amastigotes favored by this formulation, and a
simultaneous protective immunomodulation of the host immune
system.
To our knowledge this is the first demonstration of robust
effective treatment against infection with SSG-resistant Leishmania
parasites in mice with a liposomal SSG formulation. Previously
reported anionic or neutral liposomal pentavalent antimonial
formulations [19–25] were largely restricted to SSG-responsive
strains alone, except one where differential organ dependent
response was observed in primary infection model with SSG-
resistant parasites [26]. As an extension to our previous
observations on the therapy of PC-SA-SSG against SSG-sensitive
L. donovani [29], we herein observed an equipotent effect of this
therapy against non-healing infection with SSG-resistant parasites
in BALB/c mice. Resistance mechanisms in clinical isolates differ
from those active in laboratory generated strains [11]. PC-SA-SSG
was equally effective against differentially originated GE1F8R and
CK1R reflecting its strain independent antileishmanial activity. A
single dose of 12 mg/kg of PC-SA-SSG was remarkably effective
not only against liver but also splenic and bone marrow parasites
Figure 6. Humoral and antigen-specific proliferative response following treatment with PC-SA-SSG. (A, B) Sera from treated mice were
analyzed individually by ELISA for detection of IgG1 and IgG2a antibodies in GE1F8R and CK1R-infected groups of mice (3-5 mice/group). The results
are representative of two independent experiments and data represent mean 6 SEM. * p,0.05 compared to PBS treatment. (C, D) Total, and CD4+
and CD8+ T cell-depleted splenocytes from treated groups were stimulated in vitro with Leishmania membrane antigen (LAg) (12.5 mg/ml). After 48 h,
[3H] thymidine was added and cells were harvested subsequently. Proliferative index was measured as [3H] thymidine incorporation in counts per
minute. Data represent mean 6 SEM (3 mice/group) in triplicates. * p,0.05 compared to AmB therapy.
doi:10.1371/journal.pone.0017376.g006
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which was even better than AmB therapy. There was a 105-fold
fall in viable parasites with less than 100 viable parasites observed
in the organs after PC-SA-SSG therapy, which is a clear indication
of nearly complete healing. In comparison, PC-Chol-SSG
exhibited incompetence against SSG-resistant parasites. It is well
known in VL that a successful therapy may not clear all the
parasites from sites of infection but most T cell intact patients show
long lasting clinical cure despite the presence of residual
intracellular parasites [45]. Whereas PC-SA-SSG effectively
controlled parasite visceralization on a secondary attack, AmB
showed only a partial protection to reinfection, further strength-
ening the superiority of this formulation.
Figure 7. Differential pattern of cytokine and NO production following therapy with antileishmanial formulations in infected BALB/
c mice. Splenocytes isolated from GE1F8R and CK1R-infected mice after indicated treatments were plated aseptically, and stimulated with LAg
(12.5 mg/ml) for 72 h. (A, C) IFN-c, IL-12, TNF-a and (B, D) IL-10, TGF-b, IL-4 cytokine levels in supernatants of splenocyte cultures were assayed by
ELISA. Total, and CD4+ and CD8+ T cell-depleted splenocytes were stimulated as above and (E) IFN-c and (F) IL-10 levels were measured after 72 h.
Values represent the mean 6 SEM (3–5 mice/group). (G) Leishmanicidal NO generation determined by Greiss assay method in supernatants of
splenocytes derived from indicated groups. Data represent the mean 6 SEM (3–5 mice/group). * p,0.05 compared to (A, C) PBS or (B, D,G) AmB
therapy.
doi:10.1371/journal.pone.0017376.g007
Cure against SSG-Resistant Leishmania Infection
PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e17376
Prior experimental and clinical observations have pointed
towards the importance of T cell mediated protective post-
treatment mechanism in VL [45]. We tested the immunological
outcome after chemotherapy in SSG-resistant L. donovani-infected
mice treated with various therapies. Disease severity in BALB/c
mice infected with SSG-resistant strains was associated with
significantly hampered Ag-specific T cell proliferation, low
expression of IL-12, TNF-a, IFN-c and upregulation of suppres-
sive cytokines IL-10 and TGF-b. Detailed immunological analysis
of AmB and PC-SA-SSG treated mice showed enhanced T cell
proliferation, persistent IgG1 levels, probably maintained by
continued secretion of IL-4 [46,47] along with increased IgG2a
and upregulated IL-12 and IFN-c production in LAg-pulsed
splenocytes, which was lacking in PC-Chol-SSG treated group.
Treatment with PC-SA-SSG also increased the level of another
proinflammatory cytokine, TNF-a, which probably stimulates IL-
12 driven IFN-c secretion. Strong IL-12 driven IFN-c and TNF-a
triggering in PC-SA-SSG versus PC-Chol-SSG treatment suggests
that these cytokines might be involved in the observed upregulated
NO secretion for providing impressive levels of protection.
Although AmB induced significant Th1 responses, it failed to
sufficiently suppress IL-10 and TGF-b production. On the other
hand, PC-SA-SSG led to strong suppression of IL-10 and TGF-b
production that correlated with successful resolution of infection.
A growing body of literature correlates IL-10 and TGF-b with
susceptibility to Leishmania infection [48–54,42]. Since dominant
host immunity over persistent infection was achieved by an
ongoing Th1 response in the absence of immunosuppressive
cytokines, animals treated with PC-SA-SSG could effectively
prevent reinfection.
>Such a profound leishmanicidal potential of SA-bearing
SSG formulation against SSG-resistant parasites prompted us
to investigate the probable mechanisms for this phenomenon.
PC-SA-SSG treatment of infected macrophage cultures demon-
strated a direct killing of parasites concomitant with a higher
SSG accumulation inside the amastigotes. The leishmanicidal
activity of the cationic PC-SA-SSG may be due to their
preferential uptake by the macrophages [55] followed by their
cytotoxic action in the parasitophorous vacuoles. Killing of
parasites by PC-SA occurs through specific interactions of
the liposomes with the parasite membrane phosphatidylserine
(PS), leading to membrane disruption and depletion in cytosolic
ATP levels [30]. The ATP-energized efflux transporters on
parasite membranes responsible for the intracellular accumulation
of drug [56] probably are rendered nonfunctional by PC-SA-SSG,
enhancing SSG accumulation within resistant parasites. Addition-
ally, liposomes are known to circumvent the action of membrane
associated efflux pumps providing an alternate strategy to over-
come drug resistance by increasing intracellular drug accumula-
tion [32,34]. There are also reports that SA-bearing liposomes
are less leaky towards cationic drugs [57]. We used two dyes of
different nature, Rh 123 which is entrapped in the lipid phase
of the liposome and CF which is entrapped in the aqueous core.
In addition, our aim behind using Rh 123 and CF was to
assess their release profiles and see if PC-SA incorporation can
increase their retention within resistant parasites, as the former
is a well known Pgp substrate [34] and latter is known to be
transported by proteins of the MRP transporter family [38]. Efflux
of SSG in SSG-unresponsive parasites has been attributed to
similar cellular processes [56]. Interestingly, PC-SA enhanced
the intracellular retention of both the dyes, which are otherwise
vigorously thrown out of the resistant cells [34,58]. Although
we didn’t perform any experiments to confirm which efflux
pumps is actually blocked, inhibited or downregulated in this
case, but the retention studies clearly indicate a general decrease
in efflux rates when liposomal incorporation was done. Thus,
increased retention and slow release of the entrapped drug
at the site of action add to the therapeutic advantage of
PC-SA-SSG.
Cationic SA-bearing liposomes, in addition to having antil-
eishmanial activity, greatly enhance the immunogenicity of
associated antigens [40]. Antimonials can act effectively in the
presence of a propicious immune response [59]. In view of our in
vitro experiments on normal mice, it is clear that SSG exerted an
inhibitory effect on IL-10 production that was augmented by
incorporation in PC-SA liposomes. In vitro studies with only PC-
SA also showed downregulation of IL-10 which was not the case
with PC-Chol (data not shown). We have earlier observed
successful downregulation of IL-10 and TGF-b along with an
increase in IFN-c levels in in vivo experiments on normal mice
with only PC-SA [31,60]. The exact mechanism for the IL-10
downregulation and effective generation of NO, however,
remains unclear. SSG treatment is known to activate mitogen-
activated protein kinase p38 (MAPK p38) and subsequently
release TNF-a, which result in the production of NO in
macrophages [61]. Recent reports suggest that resistant parasites
modulate the host immunity to induce unresponsiveness to SSG
therapy [62]. Moreover, SSG availability in resistant parasites is
less, rendering the drug ineffective in the generation of host
microbicidal molecules. As reported earlier [63], PC-SA lipo-
somes may also activate the MAPK p38 pathway, in addition to
increasing the intracellular retention of SSG. Any drug or drug
combination activating the macrophage CD40 induced MAPK
p38 pathway can also boost the IL-12 mediated antiparasitic
function and ameliorate Leishmania infection by reinstating Th1
response [64-66]. At the doses used, it is possible that PC-SA,
along with SSG induces a MAPK mediated signalling pathway,
downregulating the pro-parasitic IL-10 secretion, ultimately
leading to killing of the parasite and restoration of the protective
immunity.
Promising therapeutic effect and protection against SSG-
unresponsive L. donovani infection can be attributed to multiple
driving forces exerted by the combined activity of SSG and PC-SA
leading to enhanced accumulation of SSG within parasites, direct
killing of parasites induced by PC-SA and the switch of
immunosuppressive humoral and cell-mediated responses to a
protective Th1 type. This synergistic approach gains importance
in today’s scenario where it can help save some of the potent drugs
against infectious diseases which are facing extinction due to
emergence of resistance, since resistance to a combination therapy
is less likely to occur.
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